Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy.

Luderer MJ, Muz B, Alhallak K, Sun J, Wasden K, Guenthner N, de la Puente P, Federico C, Azab AK.

Pharm Res. 2019 Aug 7;36(10):144. doi: 10.1007/s11095-019-2670-z.

PMID:
31392417
2.

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.

Muz B, Buggio M, Azab F, de la Puente P, Fiala M, Padval MV, Weaver DT, Pachter JA, Vij R, Azab AK.

Haematologica. 2019 Jul;104(7):e310-e313. doi: 10.3324/haematol.2018.194688. Epub 2019 Jan 17. No abstract available.

3.

System Transparency in Shared Autonomy: A Mini Review.

Alonso V, de la Puente P.

Front Neurorobot. 2018 Nov 30;12:83. doi: 10.3389/fnbot.2018.00083. eCollection 2018. Review.

4.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.

J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.

5.

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.

Muz B, Azab F, de la Puente P, Landesman Y, Azab AK.

Transl Oncol. 2017 Aug;10(4):632-640. doi: 10.1016/j.tranon.2017.04.010. Epub 2017 Jun 29.

6.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK.

Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.

7.

Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.

de la Puente P, Azab AK.

Eur J Haematol. 2017 Jun;98(6):529-541. doi: 10.1111/ejh.12870. Epub 2017 Mar 28. Review.

8.

The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.

Burwick N, Zhang MY, de la Puente P, Azab AK, Hyun TS, Ruiz-Gutierrez M, Sanchez-Bonilla M, Nakamura T, Delrow JJ, MacKay VL, Shimamura A.

Leuk Res. 2017 Apr;55:23-32. doi: 10.1016/j.leukres.2017.01.007. Epub 2017 Jan 12.

9.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.

Muz B, de la Puente P, Azab F, Azab AK.

Hypoxia (Auckl). 2015 Dec 11;3:83-92. eCollection 2015. Review.

10.

A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma.

Luderer MJ, Muz B, de la Puente P, Chavalmane S, Kapoor V, Marcelo R, Biswas P, Thotala D, Rogers B, Azab AK.

Pharm Res. 2016 Oct;33(10):2530-9. doi: 10.1007/s11095-016-1977-2. Epub 2016 Jul 11.

11.

3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

de la Puente P, Azab AK.

Future Oncol. 2016 Jul;12(13):1545-7. doi: 10.2217/fon-2016-0057. Epub 2016 Mar 30. No abstract available.

PMID:
27333447
12.

Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.

de la Puente P, Quan N, Hoo RS, Muz B, Gilson RC, Luderer M, King J, Achilefu S, Salama NN, Vij R, Azab AK.

Haematologica. 2016 Jul;101(7):e307-11. doi: 10.3324/haematol.2016.142190. Epub 2016 Apr 14. No abstract available.

13.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.

de la Puente P, Muz B, Jin A, Azab F, Luderer M, Salama NN, Azab AK.

Blood Cancer J. 2016 Feb 26;6:e399. doi: 10.1038/bcj.2016.7. No abstract available.

14.

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Muz B, de la Puente P, Azab F, Luderer MJ, King J, Vij R, Azab AK.

Br J Haematol. 2016 Apr;173(1):70-81. doi: 10.1111/bjh.13927. Epub 2016 Jan 5.

15.

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib.

Muz B, Azab F, de la Puente P, Rollins S, Alvarez R, Kawar Z, Azab AK.

Biomed Res Int. 2015;2015:417586. doi: 10.1155/2015/417586. Epub 2015 Oct 11.

16.

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.

de la Puente P, Azab F, Muz B, Luderer M, Arbiser J, Azab AK.

Leuk Lymphoma. 2016 Jul;57(7):1677-86. doi: 10.3109/10428194.2015.1099645. Epub 2015 Nov 16.

17.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, Melo JV, Griffin JD, Azab AK.

Leuk Res. 2015 Sep 9. pii: S0145-2126(15)30377-5. doi: 10.1016/j.leukres.2015.09.005. [Epub ahead of print]

18.

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

de la Puente P, Muz B, Gilson RC, Azab F, Luderer M, King J, Achilefu S, Vij R, Azab AK.

Biomaterials. 2015 Dec;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. Epub 2015 Sep 12.

19.

Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice.

Kapoor V, Khudanyan A, de la Puente P, Campian J, Hallahan DE, Azab AK, Thotala D.

Cancer Res. 2015 Sep 1;75(17):3442-5. doi: 10.1158/0008-5472.CAN-15-1412. Epub 2015 Jun 30.

20.

Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy.

Luderer MJ, de la Puente P, Azab AK.

Pharm Res. 2015 Sep;32(9):2824-36. doi: 10.1007/s11095-015-1718-y. Epub 2015 Jun 2. Review.

PMID:
26033767
21.

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Blood Cancer J. 2014 Dec 5;4:e262. doi: 10.1038/bcj.2014.82. No abstract available.

22.

Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia.

Muz B, de la Puente P, Azab F, Ghobrial IM, Azab AK.

Mol Cancer Res. 2015 Feb;13(2):263-72. doi: 10.1158/1541-7786.MCR-14-0150. Epub 2014 Sep 17.

23.

The role of hypoxia and exploitation of the hypoxic environment in hematologic malignancies.

Muz B, de la Puente P, Azab F, Luderer M, Azab AK.

Mol Cancer Res. 2014 Oct;12(10):1347-54. doi: 10.1158/1541-7786.MCR-14-0028. Epub 2014 Aug 26. Review.

24.

Delivery systems for brachytherapy.

de la Puente P, Azab AK.

J Control Release. 2014 Oct 28;192:19-28. doi: 10.1016/j.jconrel.2014.06.057. Epub 2014 Jul 5. Review.

PMID:
25008970
25.

Molecularly targeted therapies in multiple myeloma.

de la Puente P, Muz B, Azab F, Luderer M, Azab AK.

Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16. Review.

26.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.

Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK.

Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734. Epub 2014 Jan 9.

PMID:
24405121
27.

Cell culture in autologous fibrin scaffolds for applications in tissue engineering.

de la Puente P, Ludeña D.

Exp Cell Res. 2014 Mar 10;322(1):1-11. doi: 10.1016/j.yexcr.2013.12.017. Epub 2013 Dec 28. Review.

PMID:
24378385
28.

Contemporary drug therapies for multiple myeloma.

de la Puente P, Azab AK.

Drugs Today (Barc). 2013 Sep;49(9):563-73. doi: 10.1358/dot.2013.49.9.2020941. Review.

PMID:
24086952
29.

Cell trafficking of endothelial progenitor cells in tumor progression.

de la Puente P, Muz B, Azab F, Azab AK.

Clin Cancer Res. 2013 Jul 1;19(13):3360-8. doi: 10.1158/1078-0432.CCR-13-0462. Epub 2013 May 10. Review.

30.

Differentiation within autologous fibrin scaffolds of porcine dermal cells with the mesenchymal stem cell phenotype.

de la Puente P, Ludeña D, López M, Ramos J, Iglesias J.

Exp Cell Res. 2013 Feb 1;319(3):144-52. doi: 10.1016/j.yexcr.2012.10.009. Epub 2012 Nov 1.

PMID:
23124076
31.

Impact of two adjustable-autonomy models on the scalability of single-human/multiple-robot teams for exploration missions.

Valero-Gomez A, de la Puente P, Hernando M.

Hum Factors. 2011 Dec;53(6):703-16.

PMID:
22235531
32.

Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering.

de la Puente P, Ludeña D, Fernández A, Aranda JL, Varela G, Iglesias J.

J Biomed Mater Res A. 2011 Dec 15;99(4):648-54. doi: 10.1002/jbm.a.33231. Epub 2011 Sep 27.

PMID:
21954088

Supplemental Content

Loading ...
Support Center